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Abstract—Several new pyridazino[10,60:1,2]pyrido[3,4-b]indol-5-inium derivatives were synthesised from b-carboline derivatives and
their cytotoxic activity and eﬀect on the cell cycle were evaluated against L1210 cancer cells.# 2002 Elsevier Science Ltd. All rights
reserved.
The term intercalator is applied to those compounds hav-
ing a planar chromophore capable of stacking between the
DNA base pairs.1,2 Intercalation provokes conformational
changes in the double helix, with consequences on the
normal mechanisms of DNA replication, transcription,
and repair.3 Interferences with these functions usually
results in non-speciﬁc cell killing.4 Thus, potential appli-
cations can be devised in the ﬁeld of antitumor drugs.57
A class of DNA intercalating agents is constituted by
charged molecules, with azinium8 and quinolizinium913
salts being the most representative examples of this kind
of polycyclic cations (Fig. 1). Our interest in the ﬁeld
focussed our studies on DNA intercalators having a
bridgehead quaternary nitrogen, and led us to prepare
some benzimidazolium9,10 and g-carbolinium1113
cations, which showed intercalating properties1013 and
in vitro antiproliferative activity.9
The very related pyridazino[10,60:1,2]pyrido[3,4-b]indol-
5-inium system has been also previously prepared in our
laboratory by condensation of a b-carbolinium salt with
1,2-dicarbonyl14 derivatives (Westphal reaction). The
method was applied to the synthesis of the naturally
occurring alkaloid ﬂavocorylene and related zwitter-
ionic indolo[2,3-a]quinolizinium compounds.15
Continuing our work in the ﬁeld, we describe in
this communication the synthesis of several new
pyridazino[10,60:1,2]pyrido[3,4-b]indol-5-inium deriva-
tives and their in vitro antiproliferative activity against
L1210 leukaemia cell line. Starting from commercially
available b-carboline derivatives harmane (1), harmol (2)
or harmine (3), a series of compounds 4 (harmane series), 5
(harmol series) and 6 (harmine series) were prepared, with
variations at the domains 1 (bromo, nitro, amino, alkoxy
or hydroxy), 2 (carbamate, ester, amide, aliphatic satu-
rated or unsaturated) and 3 (aliphatic saturated, unsatu-
rated or aromatic) (Fig. 2).
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Figure 2. Starting materials 1–3 and general structure and domains
explored for compounds 4–6.
Figure 1. General structure for azinium and quinolizinium DNA
intercalating agents.
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From 1, bromo or nitro derivatives 7 were pre-
pared.16,17 On the other hand, 1 was alkylated at the
indolic nitrogen to give 8. Amination of 7 and 8 with
O-(mesitylsulfonyl)hydroxylamine (MSH)18,19 gave
N-amino-b-carbolinium derivatives 9, which then were
reacted with 1,2-diketones through a Westphal reac-
tion, to give 4a–c and 4f–h. Some 4 derivatives, unsub-
stituted at the indolic position, were then treated with
base to give the ylide 10, which was then alkylated to give
4d–e. Finally, for 4h, reduction with stannous chloride
yielded 4i (Scheme 1 and Table 1).
From 2, indolic nitrogen was ﬁrst protected as terc-
butoxy carbamate 11. Amination with MSH yielded 12,
which was then reacted with 3,4-hexanedione under
Westphal process to give 13. Carbamate was depro-
tected in acidic media to yield 5a. On the other hand, 11
was reacted through a Williamson reaction with several
alkyl halides to give 14. Further reaction with MSH to
give 15 and then, Westphal reaction with several
1,2-diketones led to 5b–l. For compounds 5k and 5l,
treatment with hydrobromic acid yielded 5m and 5n
(Scheme 2 and Table 1).
The last series were prepared from 3. First, alkylation at
the indolic nitrogen gave 16, which was then reacted
with MSH to give 17. On the other hand, 3 was ami-
nated by MSH to yield 18.15 Then, Westphal reaction
was performed on 17 and 18 to give 6c–g and 6a,b
respectively. Finally, compounds 6a and 6b were treated
with base to give 19 which was then alkylated to yield
6h–k. When the indolic nitrogen in 6 was substituted
with an aliphatic chain bearing an ester group (6i–k)
then, alkylation must be carried out after Westphal
reaction, otherwise this reaction would completely fail.
(Scheme 3 and Table 1).
Scheme 1. Reagents and conditions: (a) Br2, THF or HNO3; (b) RX,
KOH, K2CO3, MeCN; (c) MSH, CH2Cl2; (d) 1,2-diketone, Et3N,
EtOH, reﬂux; (e) Et3N, H2O; (f) R
1X, mw, 10 min, 300 watt, two runs
or R1X, CH2Cl2; (g) SnCl2, HCl, reﬂux.
Scheme 2. Reagents and conditions: (a) Boc2O, Et3N, DMAP,
CH2Cl2; (b) MSH, CH2Cl2; (c) 1,2-diketone, Et3N, EtOH, reﬂux; (d)
HBr, acetone, reﬂux; (e) RX, KOH, K2CO3, MeCN.
Scheme 3. Reagents and conditions: (a) RX, KOH, K2CO3, MeCN;
(b) MSH, CH2Cl2; (c) 1,2-diketone, Et3N, EtOH, reﬂux; (d) Et3N,
H2O; (e) R
1X, mw, 10 min, 300 watt, two runs or RX, CH2Cl2.
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Cytotoxic activity
Compounds 4–6 were tested in vitro against L1210 leu-
kaemia and for their eﬀect on the L1210 cell cycle.20,21
Results are reported in Table 1.
The activity data show that compounds 5i and 5j were
the most active in the harmol series. In the harmine
series compounds 6d and 6e were the most active pre-
pared so far. They showed good activity as compared to
adriamycin and camptothecin.22 From cytotoxicity data
it can be deduced than a lypophillic side chain, more
than seven atoms long at C10-position is preferred in
domain 1 (5i, 5j). For domain 2, lypophillic chains at
least ﬁve atoms long give better activities (6d, 6e). In
domain 3, aliphatic groups are preferred. On the other
hand, it is interesting to notice than the most cytotoxic
compounds have eﬀect in the G1 phase of the cell cycle
while the reference compounds exert their eﬀect in the
G2M phase.
As a result, a series of new pyridazino[10,60:1,2]pyrido[3,4-
b]indol-5-inium derivatives have been prepared and their
cytotoxic activity tested in vitro against L1210 leukaemia
and for their eﬀect on the L1210 cell cycle. Two com-
pounds, 6d and 6e showed activity at the same level than
adriamycin and camptothecin, and exert their eﬀect in the
G1 phase of the cell cycle.
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d
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d
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e NS 10d
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